Literature DB >> 18370517

Determining the effectiveness of torasemide and furosemide in heart failure: design of a randomised comparison using the regenstrief medical record system.

M D Murray1, W M Tierney, D C Brater.   

Abstract

OBJECTIVE: A state-of-the-art clinical computing system was investigated to test the hypothesis of whether a completely and predictably absorbed loop diuretic (torasemide) offers clinical advantages over a diuretic that is poorly and erratically absorbed (furosemide). PATIENTS: We enrolled 234 patients with heart failure into this randomised, prospective, open-label study of the effectiveness and cost effectiveness of torasemide and furosemide with a comprehensive electronic medical record called the Regenstrief Medical Record System (RMRS) serving as the primary data repository.
METHODS: The RMRS contained patient data for physician visits, emergency department visits, hospitalisations, laboratory tests, prescription medications, and in- and outpatient service charges. Because these patient data were captured during the course of routine care, there was much efficiency in study data collection and few associated costs. Before the study began, ready access to the RMRS data permitted characterisation of the target study population and an accurate sample size calculation. During the study, programs contained within the RMRS identified patients for recruitment, preserved randomisation, and alerted investigators to important patient events. Quality-of-life instruments programmed into notebook computers were loaded with available RMRS data and then supplemented with primary collection data, thereby permitting paperless data entry.
CONCLUSION: The computing infrastructure used for this study has permitted us to examine an interface between clinical pharmacology and outcomes research within the realm of medical informatics.

Entities:  

Year:  1998        PMID: 18370517     DOI: 10.2165/00044011-199816010-00006

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  17 in total

1.  The Regenstrief Medical Record System: 20 years of experience in hospitals, clinics, and neighborhood health centers.

Authors:  C J McDonald; W M Tierney; J M Overhage; D K Martin; G A Wilson
Journal:  MD Comput       Date:  1992 Jul-Aug

Review 2.  Clinical and economic factors in the treatment of congestive heart failure.

Authors:  R Andrews; A J Cowley
Journal:  Pharmacoeconomics       Date:  1995-02       Impact factor: 4.981

Review 3.  Renal and extrarenal sites of action of diuretics.

Authors:  G Giebisch; G Klein-Robbenhaar; J Klein-Robbenhaar; K Ratheiser; R Unwin
Journal:  Cardiovasc Drugs Ther       Date:  1993-01       Impact factor: 3.727

4.  Prevalence and mortality rate of congestive heart failure in the United States.

Authors:  D D Schocken; M I Arrieta; P E Leaverton; E A Ross
Journal:  J Am Coll Cardiol       Date:  1992-08       Impact factor: 24.094

Review 5.  Acute and long term effects of loop diuretics in heart failure.

Authors:  F Krück
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 6.  Clinical pharmacology of loop diuretics.

Authors:  D C Brater
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 7.  Torasemide. A review of its pharmacological properties and therapeutic potential.

Authors:  H A Friedel; M M Buckley
Journal:  Drugs       Date:  1991-01       Impact factor: 9.546

Review 8.  Torasemide. An update of its pharmacological properties and therapeutic efficacy.

Authors:  C J Dunn; A Fitton; R N Brogden
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

9.  Dissociation between exertional symptoms and circulatory function in patients with heart failure.

Authors:  J R Wilson; G Rayos; T K Yeoh; P Gothard; K Bak
Journal:  Circulation       Date:  1995-07-01       Impact factor: 29.690

10.  Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure.

Authors:  D L Vargo; W G Kramer; P K Black; W B Smith; T Serpas; D C Brater
Journal:  Clin Pharmacol Ther       Date:  1995-06       Impact factor: 6.875

View more
  3 in total

1.  Healthcare costs of patients with heart failure treated with torasemide or furosemide.

Authors:  K T Stroupe; M M Forthofer; D C Brater; M D Murray
Journal:  Pharmacoeconomics       Date:  2000-05       Impact factor: 4.981

2.  Torasemide: a pharmacoeconomic review of its use in chronic heart failure.

Authors:  M Young; G L Plosker
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

3.  Social support and health-related quality of life in chronic heart failure patients.

Authors:  S J Bennett; S M Perkins; K A Lane; M Deer; D C Brater; M D Murray
Journal:  Qual Life Res       Date:  2001       Impact factor: 4.147

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.